MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$84,922K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net proceeds from issuance of co...
Sales and maturities of marketab...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
General and administrative
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
7,659
15,048
23,017
44,654
Research and development
82,595
80,737
88,652
300,209
General and administrative
37,824
34,843
33,075
86,725
Interest income
5,797
5,205
6,476
22,719
Loss from equity method investment
-
-
0
-
Other segment information
-329
904
1,754
-2,653
Net loss
-106,634
-96,231
-95,786
-101,324
Depreciation and amortization
2,082
2,202
2,380
2,415
Gain on disposal of property and equipment
-
-
-
0
Loss on disposal of property and equipment
-153
-
-527
-
Accelerated amortization/impairment of right-of-use assets
-
-
3,635
2,521
Stock-based compensation
18,075
13,479
16,739
19,604
Accretion of investment discounts
614
535
826
1,085
Recognition of equity method investment intra-entity profit on sales
-
-
-
0
Change in fair value of investments, net
329
-904
-3,552
3,439
(recognition) deferral of equity method investment intra-entity profit on sales
-
-
0
-
Loss from equity method investment
-
-
0
-
Change in fair value of contingent consideration
-
-
0
-
Accounts receivable
-1,810
-337
-1,582
-303
Prepaid expenses and other current assets
1,419
12,972
8,690
23,035
Operating lease right-of-use assets
-9,507
-8,411
-8,294
-8,641
Other assets
-612
74
-1,938
-25,288
Accounts payable
-7,086
-1,420
6,959
3,459
Accrued expenses
6,356
-11,947
9,027
-715
Deferred revenue
-630
-6,660
-13,980
-4,907
Operating lease liabilities
-4,996
-12,840
-4,636
-4,625
Net cash used in operating activities
-83,113
-117,346
-69,285
-76,899
Purchases of property and equipment
1,809
79
126
29
Proceeds from sale of property and equipment
90
-
-
-
Purchases of marketable securities
220,393
46,965
67,050
116,651
Sales and maturities of marketable securities
80,540
113,354
94,710
115,939
Net cash (used in) provided by investing activities
-141,572
66,310
27,534
-741
Net proceeds from issuance of common stock-Follow On Public Offering
194,580
-
-
-
Net proceeds from issuance of common stock
-
-
128,175
-
Net proceeds from issuance of common stock-At The Market Offerings
0
-94,606
-
114,760
Proceeds from options exercised
16
-
625
97
Issuance of shares through employee stock purchase plan
1,520
-
1,352
0
Net cash provided by financing activities
196,116
33,569
1,977
114,857
Net decrease in cash, cash equivalents and restricted cash equivalents
-28,569
-17,467
-39,774
37,217
Cash, cash equivalents and restricted cash equivalents, beginning of period
150,101
167,568
207,342
202,787
Cash, cash equivalents and restricted cash equivalents, end of period
121,532
-
-
-
Cash and cash equivalents
106,128
-
-
-
Restricted cash equivalents, included in investments and other assets
15,404
-
-
-
Total cash, cash equivalents and restricted cash equivalents
121,532
150,101
167,568
207,342
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net proceeds from
issuance of common...
$194,580K
Issuance of shares
through employee stock...
$1,520K
(22.88%↑ Y/Y)
Proceeds from options
exercised
$16K
Net cash provided by
financing activities
$196,116K
(1238.49%↑ Y/Y)
Net decrease in
cash, cash...
-$28,569K
(12.53%↑ Y/Y)
Canceled cashflow
$196,116K
Sales and maturities
of marketable...
$80,540K
(-76.38%↓ Y/Y)
Proceeds from sale of
property and equipment
$90K
Stock-based compensation
$18,075K
(-58.80%↓ Y/Y)
Operating lease
right-of-use assets
-$9,507K
(41.14%↑ Y/Y)
Accrued expenses
$6,356K
(146.79%↑ Y/Y)
Depreciation and
amortization
$2,082K
(-58.13%↓ Y/Y)
Accounts receivable
-$1,810K
(-163.82%↓ Y/Y)
Other assets
-$612K
(-102.51%↓ Y/Y)
Loss on disposal of
property and equipment
-$153K
Net cash (used in)
provided by investing...
-$141,572K
(-170.35%↓ Y/Y)
Canceled cashflow
$80,630K
Net cash used in
operating activities
-$83,113K
(66.56%↑ Y/Y)
Canceled cashflow
$38,595K
Collaboration revenue
$7,659K
Interest income
$5,797K
Other segment
information
-$329K
Purchases of marketable
securities
$220,393K
(58.77%↑ Y/Y)
Purchases of property and
equipment
$1,809K
(85.73%↑ Y/Y)
Net loss
-$106,634K
(50.54%↑ Y/Y)
Canceled cashflow
$13,785K
Accounts payable
-$7,086K
(-59.92%↓ Y/Y)
Operating lease
liabilities
-$4,996K
(89.07%↑ Y/Y)
Prepaid expenses and
other current assets
$1,419K
(126.41%↑ Y/Y)
Deferred revenue
-$630K
(93.17%↑ Y/Y)
Accretion of investment
discounts
$614K
(-84.44%↓ Y/Y)
Change in fair value of
investments, net
$329K
(141.86%↑ Y/Y)
Research and development
$82,595K
General and
administrative
$37,824K
Buy us a coffee
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)